Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 20/20 | 0.74 |
| ▸ | HCRTR2 | O43614 | 20/20 | 0.74 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29521524 | 1.00 | HCRTR1 (0.74) | HCRTR1HCRTR2KCNH2 | |
| SCHEMBL24533939 | 1.00 | HCRTR1 (0.74) | HCRTR1HCRTR2KCNH2 | |
| SCHEMBL22666388 | 1.00 | HCRTR1 (0.74) | HCRTR1HCRTR2KCNH2 | |
| SCHEMBL26350991 | 0.92 | HCRTR1 (0.74) | HCRTR1HCRTR2KCNH2 | |
| SCHEMBL16638936 | 0.92 | HCRTR1 (0.74) | HCRTR1HCRTR2KCNH2 | |
| SCHEMBL26350983 | 0.92 | HCRTR1 (0.74) | HCRTR1HCRTR2KCNH2 | |
| SCHEMBL2610558 | 0.92 | HCRTR1 (0.74) | HCRTR1HCRTR2KCNH2 | |
| SCHEMBL26351279 | 0.92 | HCRTR1 (0.74) | HCRTR1HCRTR2KCNH2 | |
| SCHEMBL26350998 | 0.91 | HCRTR1 (0.73) | HCRTR1HCRTR2KCNH2 | |
| SCHEMBL28928604 | 0.90 | HCRTR1 (0.75) | HCRTR1HCRTR2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023178693-A1 | METHOD FOR PREPARING LEMBOREXANT AND METHOD FOR PREPARING LEMBOREXANT INTERMEDIATE | 浙江华海药业股份有限公司 | 2023-09-28 | — | — | WO | disclosed |
| WO-2023178693-A1 | METHOD FOR PREPARING LEMBOREXANT AND METHOD FOR PREPARING LEMBOREXANT INTERMEDIATE | 浙江华海药业股份有限公司 | 2023-09-28 | — | — | WO | disclosed |
| WO-2023178702-A1 | METHOD FOR PREPARING LEMBOREXANT AND METHOD FOR PREPARING LEMBOREXANT INTERMEDIATE COMPOUND | 浙江华海药业股份有限公司 | 2023-09-28 | — | — | WO | disclosed |
| WO-2023178702-A1 | METHOD FOR PREPARING LEMBOREXANT AND METHOD FOR PREPARING LEMBOREXANT INTERMEDIATE COMPOUND | 浙江华海药业股份有限公司 | 2023-09-28 | — | — | WO | disclosed |
| CN-114901285-A | Raw material medicine of Leboraseng and medicine composition containing same | 卫材R&D管理有限公司 | 2022-08-12 | — | — | CN | disclosed |
| US-20220194925-A1 | METHOD AND COMPOUND USEFUL IN PREPARATION OF OREXIN-2 RECEPTOR ANTAGONIST, AND LEMBOREXANT HAVING FEW IMPURITIES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2022-06-23 | — | — | US | disclosed |
| CN-113727962-A | Methods and compounds for preparing orexin-2 receptor antagonists and lebereproduction with reduced impurities | 卫材R&D管理有限公司 | 2021-11-30 | — | — | CN | disclosed |
| US-20210347759-A1 | METHOD FOR MANUFACTURING CYCLOPROPANE COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2021-11-11 | — | — | US | disclosed |
| WO-2021145373-A1 | DRUG SUBSTANCE OF LEMBOREXANT AND MEDICINAL COMPOSITION COMPRISING SAME | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 2021-07-22 | — | — | WO | disclosed |
| EP-3848348-A1 | METHOD FOR MANUFACTURING CYCLOPROPANE COMPOUND | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 2021-07-14 | — | — | EP | disclosed |
| EP-2626350-B1 | CYCLOPROPANE COMPOUND | EISAI R&D MAN CO LTD (JP) | 2015-04-15 | — | — | EP | disclosed |
| US-20150025237-A1 | Methods and Compounds Useful in the Synthesis of Orexin-2 Receptor Antagonists | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2015-01-22 | — | — | US | disclosed |
| US-20150025237-A1 | Methods and Compounds Useful in the Synthesis of Orexin-2 Receptor Antagonists | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2015-01-22 | — | — | US | disclosed |
| US-20150025237-A1 | Methods and Compounds Useful in the Synthesis of Orexin-2 Receptor Antagonists | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2015-01-22 | — | — | US | disclosed |
| WO-2013123240-A1 | METHODS AND COMPOUNDS USEFUL IN THE SYNTHESIS OF OREXIN-2 RECEPTOR ANTAGONISTS | EISAI R&D MANAGEMENT CO., LTD (JP) | 2013-08-22 | — | — | WO | disclosed |
| EP-2626350-A1 | CYCLOPROPANE COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2013-08-14 | — | — | EP | disclosed |
| US-8268848-B2 | Cyclopropane compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-09-18 | — | — | US | disclosed |
| US-8268848-B2 | Cyclopropane compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-09-18 | — | — | US | disclosed |
| US-20120095031-A1 | CYCLOPROPANE COMPOUND | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-04-19 | — | — | US | disclosed |
| US-20120095031-A1 | CYCLOPROPANE COMPOUND | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220194925-A1 | METHOD AND COMPOUND USEFUL IN PREPARATION OF OREXIN-2 RECEPTOR ANTAGONIST, AND LEMBOREXANT HAVING FEW IMPURITIES | HCRTR2, HCRTR1, MCHR2 | HCRTR1 2/4885HCRTR2 1/4885KCNH2 1380/4885 |
| US-20120095031-A1 | CYCLOPROPANE COMPOUND | HCRTR1, HCRTR2, CNR1 | HCRTR1 1/4885HCRTR2 2/4885KCNH2 369/4885 |
| US-20150025237-A1 | Methods and Compounds Useful in the Synthesis of Orexin-2 Receptor Antagonists | HCRTR2, HCRTR1, NPY2R | HCRTR1 2/4885HCRTR2 1/4885KCNH2 2306/4885 |
| US-20210347759-A1 | METHOD FOR MANUFACTURING CYCLOPROPANE COMPOUND | DHPS, FDPS, CYP1B1 | HCRTR1 3618/4885HCRTR2 2977/4885KCNH2 1019/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.